Top 10 Challenges: Producing commercial cell and gene products
The international regenerative medicines market – which includes the likes of cell therapies, gene/gene-modified cell therapy and tissue engineering – is set to climb to around $67 billion by 2020. Alongside, discovering therapies that will treat cancer and orphan diseases, many in the industry are hungry to land grab market share and produce the next blockbuster product.
Pharma IQ spoke to Dieter Hauwaerts, VP Operations, Celyadand other industry experts about the top challenges in the Manufacturing Commercialised Cell & Gene Therapies sector.
Download this piece to learn more about:
- Product quality awareness and how functionality tests make manufacturing in a QbD space difficult
- How Downstream processing times that are elongated can have a direct impact on cell quality as the scale is upped
- How stable funding is hard to access with the lengthy R&D timelines and changing regulatory parameters that surround cell and gene therapies
Please note: That all fields marked with an asterisk (*) are required.